Clinical Trial Update: Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

View source ↗

Summary

This clinical trial update estimates malignancy rates in Humedica patient populations sampled to represent liraglutide initiators and LEADER trial participants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Status: COMPLETED